Back to Search
Start Over
Rituximab therapy for refractory systemic-onset juvenile idiopathic arthritis: Table 1
- Source :
- Annals of the Rheumatic Diseases. 68:607-608
- Publication Year :
- 2009
- Publisher :
- BMJ, 2009.
-
Abstract
- Systemic-onset juvenile idiopathic arthritis (SOJIA), formerly called Still’s disease, is a subset of juvenile arthritis that describes patients with fever, rash, arthritis, serositis and visceromegaly. In up to 30% of cases the disease has a chronic course and management requires high doses of glucocorticoids, disease-modifying antirheumatic drugs (DMARD), tumour necrosis factor alpha (TNFα) inhibitors or anakinra.1–6 However, this therapeutic arsenal is unable to control the disease in all patients. Recently, rituximab, a chimeric anti-CD20 monoclonal antibody, has been successfully used in two patients with refractory adult-onset Still’s disease.7 As the similarity of clinical and laboratory features present in SOJIA and adult-onset Still’s disease implies that these conditions have similar …
- Subjects :
- business.industry
Immunology
Arthritis
medicine.disease
Rash
General Biochemistry, Genetics and Molecular Biology
Systemic-onset juvenile idiopathic arthritis
Antirheumatic Agents
Rheumatology
medicine
Immunology and Allergy
Methotrexate
Rituximab
medicine.symptom
business
Serositis
Visceromegaly
medicine.drug
Subjects
Details
- ISSN :
- 14682060 and 00034967
- Volume :
- 68
- Database :
- OpenAIRE
- Journal :
- Annals of the Rheumatic Diseases
- Accession number :
- edsair.doi...........53775d813dc9e022218d83d43a6b27de